Evidence map›Paper›PMID 35127160›Full record

ArticleJournal of advanced research2022

Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation.

Jingyu Zhu, Kan Li, Lei Xu, Yanfei Cai, Yun Chen, Xinling Zhao, Huazhong Li, Gang Huang, Jian Jin

Open access · goldAbstract read
In one paragraph

Article in Journal of advanced research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Isovaleryl Sucrose Esters fromMolecules (Basel, Switzerland) · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jingyu ZhuSchool of Pharmaceutical Sciences, Jiangnan University, Wuxi, Jiangsu 214122, China.
Kan LiSchool of Pharmaceutical Sciences, Jiangnan University, Wuxi, Jiangsu 214122, China.
Lei XuInstitute of Bioinformatics and Medical Engineering, School of Electrical and Information Engineering, Jiangsu University of Technology, Changzhou 213001, China.
Yanfei CaiSchool of Pharmaceutical Sciences, Jiangnan University, Wuxi, Jiangsu 214122, China.
Yun ChenSchool of Pharmaceutical Sciences, Jiangnan University, Wuxi, Jiangsu 214122, China.
Xinling ZhaoSchool of Pharmaceutical Sciences, Jiangnan University, Wuxi, Jiangsu 214122, China.
Huazhong LiSchool of Biotechnology, Jiangnan University, Wuxi, Jiangsu 21412 2, China.
Gang HuangShanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
Jian JinSchool of Pharmaceutical Sciences, Jiangnan University, Wuxi, Jiangsu 214122, China.
Jiangnan University · CNJiangsu University of Technology · CNShanghai University of Medicine and Health Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Phosphoinositide 3-kinase gamma (PI3Kγ) has been regarded as a promising drug target for the treatment of various diseases, and the diverse physiological roles of class I PI3K isoforms (α, β, δ, and γ) highlight the importance of isoform selectivity in the development of PI3Kγ inhibitors. However, the high structural conservation among the PI3K family makes it a big challenge to develop selective PI3Kγ inhibitors. Objectives: A novel machine learning-based virtual screening with multiple PI3Kγ protein structures was developed to discover novel PI3Kγ inhibitors. Methods: A large chemical database was screened using the virtual screening model, the top-ranked compounds were then subjected to a series of bio-evaluations, which led to the discovery of JN-KI3. The selective inhibition mechanism of JN-KI3 against PI3Kγ was uncovered by a theoretical study. Results: 49 hits were identified through virtual screening, and the cell-free enzymatic studies found that JN-KI3 selectively inhibited PI3Kγ at a concentration as low as 3,873 nM but had no inhibitory effect on Class IA PI3Ks, leading to the selective cytotoxicity on hematologic cancer cells. Meanwhile, JN-KI3 potently blocked the PI3K signaling, finally led to distinct apoptosis of hematologic cell lines at a low concentration. Lastly, the key residues of PI3Kγ and the structural characteristics of JN-KI3, which both would influence γ isoform-selective inhibition, were highlighted by systematic theoretical studies. Conclusion: The developed virtual screening model strongly manifests the robustness to find novel PI3Kγ inhibitors. JN-KI3 displays a specific cytotoxicity on hematologic tumor cells, and significantly promotes apoptosis associated with the inhibition of the PI3K signaling, which depicts PI3Kγ as a potential target for the hematologic tumor therapy. The theoretical results reveal that those key residues interacting with JN-KI3 are less common compared to most of the reported PI3Kγ inhibitors, indicating that JN-KI3 has novel structural characteristics as a selective PIK3γ inhibitor.

Indexed as

Molecular Dynamics SimulationPhosphatidylinositol 3-KinasesMachine LearningMolecular Docking SimulationPhosphoinositide-3 Kinase InhibitorsPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsADMET, absorption, distribution, metabolism, excretion, and toxicityAKT, protein kinase BAUC, area under receiver operations characteristic curveBadapple, bioactivity data associative promiscuity pattern learning engineCADD, computer-aided drug designCDRA, confirmatory dose–response assaysDMEM, Dulbecco’s Modified Eagle MediumDS3.5, discovery studio 3.5FBS, fetal bovine serumGPCR, G protein-coupled receptorsH-bond, hydrogen bondHematologic malignanciesIMDM, Iscove’s Modified Dulbecco’s MediumIonic, ionic interactionsJN-KI3MD, molecular dynamicsMM/GBSA, molecular mechanics/generalized born surface areaMolecular dynamics simulationNBC, naive Bayesian classifierPAGE, polyacrylamide gel electrophoresisPAINS, pan-assay interference compoundsPARP, poly ADP-ribose polymerasePDB, protein data bankPI3K, Phosphoinositide 3-kinasePI3KγPSA, primary screening assaysREOS, rapid elimination of swillRMSD, root-mean-squared-deviationRMSF, root-mean-squared-fluctuationROC, receiver operations characteristicRTK, receptor tyrosine kinasesSD, standard deviationSelective inhibitorSMILES, simplified molecular input line entry specificationSP, standard precisionVirtual screeningVS, virtual screeningWater Bridge, hydrogen bonds through water molecular bridgeXP, extra precision

Identifiers

PMID35127160
PMCPMC8800018
OpenAlexW3154788486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.